Related references
Note: Only part of the references are listed.Genomic Aberrations in Diffuse Low-Grade Gliomas
Hanne-Sofie S. Dahlback et al.
GENES CHROMOSOMES & CANCER (2011)
Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
Albert Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis
Julien Laffaire et al.
NEURO-ONCOLOGY (2011)
Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme
R. Helseth et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference
Luca Morandi et al.
BMC CANCER (2010)
DNA methylation in glioblastoma: impact on gene expression and clinical outcome
Amandine Etcheverry et al.
BMC GENOMICS (2010)
Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
K. A. van Nifterik et al.
BRITISH JOURNAL OF CANCER (2010)
Reversing HOXA9 Oncogene Activation by PI3K Inhibition: Epigenetic Mechanism and Prognostic Significance in Human Glioblastoma
Bruno M. Costa et al.
CANCER RESEARCH (2010)
MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma
Markus Christmann et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
O 6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma
Yukihiko Sonoda et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2010)
CHEMORADIOTHERAPY OF NEWLY DIAGNOSED GLIOBLASTOMA WITH INTENSIFIED TEMOZOLOMIDE
Markus Weiler et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Association of the GNB3 825T-allele with better survival in patients with glioblastoma multiforme
Nicolai El Hindy et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study
Alessandra Fabi et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients
Francois Ducray et al.
MOLECULAR CANCER (2010)
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers
Michael Jansen et al.
LANCET NEUROLOGY (2010)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients
O. Slaby et al.
NEOPLASMA (2010)
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma
Andreana L. Rivera et al.
NEURO-ONCOLOGY (2010)
O-6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients
Sabine Spiegl-Kreinecker et al.
NEURO-ONCOLOGY (2010)
O-6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications
Alba A. Brandes et al.
NEURO-ONCOLOGY (2010)
Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades
Iris Lavon et al.
NEURO-ONCOLOGY (2010)
Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas
Bo-Lin Liu et al.
NEURO-ONCOLOGY (2010)
An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging
Sylvia Drabycz et al.
NEUROIMAGE (2010)
O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is significantly less frequent in ependymal tumours as compared to malignant astrocytic gliomas
B. Koos et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2010)
Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide
Giuseppe Minniti et al.
RADIOTHERAPY AND ONCOLOGY (2010)
The prognostic role of Beclin 1 protein expression in high-grade gliomas
Luigi Pirtoli et al.
AUTOPHAGY (2009)
RASSF1A, BLU, NORE1A, PTEN and MGMT Expression and Promoter Methylation in Gliomas and Glioma Cell Lines and Evidence of Deregulated Expression of de novo DNMTs
Aiala Lorente et al.
BRAIN PATHOLOGY (2009)
Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
J. Dunn et al.
BRITISH JOURNAL OF CANCER (2009)
Prognostic Impact of O6-Methylguanine-DNA Methyltransferase Silencing in Patients With Recurrent Glioblastoma Multiforme Who Undergo Surgery and Carmustine Wafer Implantation A Prospective Patient Cohort
Philippe Metellus et al.
CANCER (2009)
Temozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma Correlation With MGMT Promoter Methylation Status
Alba A. Brandes et al.
CANCER (2009)
Temozolomide in malignant gliomas: current use and future targets
J. Lee Villano et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations
Emilia Jesien-Lewandowicz et al.
CANCER GENETICS AND CYTOGENETICS (2009)
Association Between MGMT Promoter Hypermethylation and p53 Mutation in Glioblastoma
Jamal Shamsara et al.
CANCER INVESTIGATION (2009)
Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults
Santosh Kesari et al.
CLINICAL CANCER RESEARCH (2009)
Folate Supplementation Limits the Aggressiveness of Glioma via the Remethylation of DNA Repeats Element and Genes Governing Apoptosis and Proliferation
Eric Hervouet et al.
CLINICAL CANCER RESEARCH (2009)
Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients
Joerg Felsberg et al.
CLINICAL CANCER RESEARCH (2009)
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma
J. Sadones et al.
EUROPEAN JOURNAL OF CANCER (2009)
Genomic Aberrations in 80 Cases of Primary Glioblastoma Multiforme: Pathogenetic Heterogeneity and Putative Cytogenetic Pathways
Hanne-Sofie S. Dahlback et al.
GENES CHROMOSOMES & CANCER (2009)
Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors
Lu-Ting Kuo et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide
Martin Glas et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial
Stuart A. Grossman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma
Jennifer L. Clarke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With MGMT Promoter Methylation Status
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
Michael Weller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma
T. Mikkelsen et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas
Sibille Everhard et al.
NEURO-ONCOLOGY (2009)
Promoter Methylation and Polymorphisms of the MGMT Gene in Glioblastomas: A Population-Based Study
Izabela Zawlik et al.
NEUROEPIDEMIOLOGY (2009)
MGMT METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
E. R. Gerstner et al.
NEUROLOGY (2009)
Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin
Chul-Kee Park et al.
NEUROPATHOLOGY (2009)
THE CORRELATION AND PROGNOSTIC SIGNIFICANCE OF MGMT PROMOTER METHYLATION AND MGMT PROTEIN IN GLIOBLASTOMAS
Van Thang Cao et al.
NEUROSURGERY (2009)
Methylation Status of the O6-Methylguanine-Deoxyribonucleic Acid Methyltransferase Gene Promoter in World Health Organization Grade III Gliomas
Seung-Heon Yang et al.
JOURNAL OF KOREAN NEUROSURGICAL SOCIETY (2009)
Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme
Maurizio Martini et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
Monika E. Hegi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas
A. Tosoni et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme
Angelique E. Sijben et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
Thierry Gorlia et al.
LANCET ONCOLOGY (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas
Eva M. Grasbon-Frodl et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas
Judith Wm Jeuken et al.
LABORATORY INVESTIGATION (2007)
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma
Antje Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis
Thomas Mikeska et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2007)
MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities
Emmanuelle Criniere et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme
Ramon Martinez et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival
Marica Eoli et al.
CLINICAL CANCER RESEARCH (2007)
MGMT methylation:: A marker of response to temozolomide in low-grade gliomas
Sibille Everhard et al.
ANNALS OF NEUROLOGY (2006)
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma:: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
A. A. Brandes et al.
BRITISH JOURNAL OF CANCER (2006)
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GICNO study
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma
Jill A. Maxwell et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection
Mohammad Obaidul Hoque et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas
M Brell et al.
CLINICAL CANCER RESEARCH (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
O6-Methylguanine-DNA Methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course
T Watanabe et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors
M Möllemann et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Analysis of repetitive element DNA methylation by MethyLight
DJ Weisenberger et al.
NUCLEIC ACIDS RESEARCH (2005)
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide
ME Hegi et al.
CLINICAL CANCER RESEARCH (2004)
Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-primidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy
T Kamiryo et al.
NEUROSURGERY (2004)
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas
MF Paz et al.
CLINICAL CANCER RESEARCH (2004)
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen
M Widschwendter et al.
CANCER RESEARCH (2004)
Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas
ME Alonso et al.
CANCER GENETICS AND CYTOGENETICS (2003)
Clinical relevance of MGMT in the treatment of cancer
SL Gerson
JOURNAL OF CLINICAL ONCOLOGY (2002)
Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas
T Watanabe et al.
ACTA NEUROPATHOLOGICA (2002)
Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C→A:T mutations of the TP53 tumor suppressor gene
M Nakamura et al.
CARCINOGENESIS (2001)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
